- Home
- CUE vs HOWL Comparison
CUE vs HOWL Comparison
Compare CUE & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | HOWL |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 64.5M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CUE | HOWL |
|---|---|---|
| Price | $0.37 | $0.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $3.00 | ★ $6.50 |
| AVG Volume (30 Days) | ★ 1.7M | 896.1K |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.23 | $0.56 |
| 52 Week High | $1.75 | $2.38 |
Technical Indicators
Market Signals| Indicator | CUE | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 34.09 |
| Support Level | $0.23 | $0.60 |
| Resistance Level | $0.44 | $0.74 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 57.32 | 13.54 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.